Lilly, MacroGenics Say Diabetes Treatment Misses Goal
This article is for subscribers only.
Eli Lilly & Co. and MacroGenics Inc. said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
An analysis by an independent panel of experts determined that the drug, teplizumab, was not effective in slowing the progress of Type 1 diabetes, the companies said in a statement. Lilly and MacroGenics will suspend the study, the third of three phases of clinical trials usually needed to gain U.S. regulatory approval, and two additional trials of the drug for Type 1 diabetes, Kelley Murphy, a Lilly spokeswoman, said today in a telephone interview.